SCHEMBL2559486

SCHEMBL2559486

CC(=O)c1cccc(-c2cccc(C(=O)O)n2)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.50
ALOX15 P16050 1/20 0.50
TSHR P16473 1/20 0.50
ACMSD Q8TDX5 1/20 0.50
TDP1 Q9NUW8 1/20 0.50
ERN1 O75460 1/20 0.48
MAP4K4 O95819 3/20 0.48
CLK4 Q9HAZ1 3/20 0.48
KDR P35968 2/20 0.48
MAPK8 P45983 2/20 0.48
CDK8 P49336 2/20 0.48
ACVR1 Q04771 2/20 0.48
MST1R Q04912 2/20 0.48
ROCK1 Q13464 2/20 0.48
LRRK2 Q5S007 2/20 0.48
DYRK1B Q9Y463 2/20 0.48
AURKA O14965 1/20 0.48
DAPK3 O43293 1/20 0.48
JAK2 O60674 1/20 0.48
ABL1 P00519 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2553456 0.85 KDM4E (0.52) KDM4EALOX15TSHRACMSDTDP1
SCHEMBL3643213 0.84 KDM4E (0.50) KDM4EALOX15TSHRACMSDTDP1
SCHEMBL4140065 0.83 IRAK4 (0.56) KDM4EALOX15TSHRACMSDTDP1
SCHEMBL208097 0.81 KDM4E (0.64) KDM4EALOX15TSHRACMSDTDP1
SCHEMBL13680552 0.80 CYP2A6 (0.53) MAP4K4CLK4KDRMAPK8CDK8
SCHEMBL3642571 0.80 HSD17B14 (0.62) KDM4EALOX15TSHRACMSDTDP1
Hydrochloric Acid SCHEMBL29133274 0.79 KDM4E (0.61) KDM4EALOX15TSHRACMSDTDP1
SCHEMBL3057779 0.79 CNR2 (0.69) KDM4EALOX15TSHRACMSDTDP1
SCHEMBL3054255 0.79 KMO (0.63) KDM4EALOX15TSHRACMSDTDP1
SCHEMBL30900591 0.79 KMO (0.63) KDM4EALOX15TSHRACMSDTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220340893-A1 BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES NUEVOLUTION A/S (DK) 2022-10-27 US disclosed
US-11225655-B2 Bi-functional complexes and methods for making and using such complexes NUEVOLUTION A/S (DK) 2022-01-18 US disclosed
EP-3540059-A1 BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES Nuevolution A/S (DK) 2019-09-18 EP disclosed
EP-2558577-B1 BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES NUEVOLUTION AS (DK) 2018-12-12 EP disclosed
US-20130281324-A1 BI-FUNCTINAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES NUEVOLUTION A/S (DK) 2013-10-24 US disclosed
EP-2558577-A1 BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES Nuevolution A/S (DK) 2013-02-20 EP disclosed
WO-2011127933-A1 BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES NUEVOLUTION A/S (DK) 2011-10-20 WO disclosed
CN-101842362-A Benzothiazole compounds INST MEDICAL W & E HALL 2010-09-22 CN disclosed
US-20100197711-A1 BENZOTHIAZOLE COMPOUNDS THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) 2010-08-05 US disclosed
US-20100197711-A1 BENZOTHIAZOLE COMPOUNDS THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) 2010-08-05 US disclosed
US-20100197711-A1 BENZOTHIAZOLE COMPOUNDS THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) 2010-08-05 US disclosed
EP-2193127-A1 BENZOTHIAZOLE COMPOUNDS The Walter and Eliza Hall Institute of Medical Research (AU) 2010-06-09 EP disclosed
WO-2009039553-A1 BENZOTHIAZOLE COMPOUNDS THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) 2009-04-02 WO disclosed
WO-2009039553-A1 BENZOTHIAZOLE COMPOUNDS THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) 2009-04-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197711-A1 BENZOTHIAZOLE COMPOUNDS BAD, BCL2, BAX KDM4E 1470/4885ALOX15 2493/4885TSHR 3734/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.